[The use of a drug association in the treatment of concussive syndromes].
D000227:Adenine Nucleotides / Q000627:therapeutic use*; D000255:Adenosine Triphosphate / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D001924:Brain Concussion / Q000150:complications* / Q000188:drug therapy; D002648:Child; D006261:Headache / Q000188:drug therapy; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy; D008875:Middle Aged; D011736:Pyridoxine / Q000627:therapeutic use*; D012893:Sleep Wake Disorders / Q000188:drug therapy; D014500:Uracil Nucleotides / Q000627:therapeutic use*; D014717:Vertigo / Q000188:drug therapy; D014805:Vitamin B 12 / Q000627:therapeutic use*
D000227:Adenine Nucleotides; D014500:Uracil Nucleotides; D000255:Adenosine Triphosphate; D011736:Pyridoxine; D014805:Vitamin B 12
L'impiego di un'associazione farmacologica nel trattamento delle sindromi commotive.